CBD S&T Conference 2024
Florida, US, 02 - 05 Dec 2024
We are looking forward to exhibiting at the CBD S&T Conference 2024 this December. This conference brings together the most innovative and influential chemical and biological defense community members from around the globe to share insights and collaborate on the emerging chem-bio threats of tomorrow.
If you are interested in learning more about the work Owlstone Medical is doing, please get in touch to meet with us at the conference, booth 401.
Meet the Team:
Matthew Hart, VP Programme – Chemical Protection
Matthew joined Owlstone in 2006 to lead the development of the company’s micro-fabricated FAIMS ion filter. From 2007 to 2015 he held a number of technical and commercial leadership positions in Owlstone’s Defence and Security business unit, including leading a four-year project to dramatically reduce the size, weight and power consumption of Owlstone’s chemical detectors, funded by the United States Defense Threat Reduction Agency. He has also worked closely with key customers in Europe and Asia to develop Owlstone’s portable chemical detection business and has been active in securing product development funding through a number of government and commercial contracts. Since 2016, as VP Research and Development, Matthew has been responsible for Owlstone’s R&D staff and resources. Prior to joining Owlstone, he led commercial microsystems development projects at Iris AO Inc, Onix Microsystem Inc, and at the University of California, Berkeley. Matthew holds a BA in physics from The University of Oxford and a PhD in physics from the University of Edinburgh, UK.
Robert Mohney, Head of Clinical Biomarker Services
Robert Mohney’s scientific career spans >30 years in the biomedical and translational sciences, working to understand the drivers of human health and disease with the aim of disease prevention, early disease detection, and therapeutic intervention. He is the co-author of >100 peer-reviewed publications that have been cited nearly 15k times. He has extensive experience with state-of-the-art technologies for biochemical profiling, biomarker discovery, and clinical metabolomics. In his current role as Head of Clinical Biomarker Services, Rob leads a team of biologists focused on applications of volatile metabolomics profiling for identification of early disease biomarkers and precision medicine.